Law Firms Seek Lead Plaintiff in Telix Securities Case After SEC Subpoena, FDA Complete Response Letter

Investors have until January 9, 2026 to contact counsel about alleged losses tied to Telix’s February–August 2025 trading window.

Overview

A federal securities class action, Thomas v. Telix Pharmaceuticals Ltd., No. 25-cv-02299 (S.D. Ind.), names the company and certain executives for alleged violations of the Securities Exchange Act of 1934.
The proposed class encompasses purchasers of Telix securities from February 21, 2025 through August 28, 2025, inclusive.
According to the complaint, Telix overstated progress on prostate cancer therapeutics and the quality of its supply chain and partners.
Plaintiffs point to a July 22, 2025 disclosure of an SEC subpoena followed by a reported drop of more than 13% in ADSs, and an August 28, 2025 FDA Complete Response Letter for TLX250-CDx citing CMC deficiencies and supplier Form 483s followed by a reported decline of more than 21%.
Robbins Geller, the Schall Law Firm, and Bronstein, Gewirtz & Grossman are soliciting investors to seek lead-plaintiff status with a January 9, 2026 contact date, while the class is not yet certified and the allegations remain unproven.